Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $40.3 million.

  • Spyre Therapeutics' Other Non Operating Income rose 31447.72% to $40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.1 million, marking a year-over-year increase of 19963.91%. This contributed to the annual value of -$20.7 million for FY2024, which is 827.5% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Other Non Operating Income of $40.3 million as of Q3 2025, which was up 31447.72% from -$656000.0 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Other Non Operating Income ranged from a high of $40.3 million in Q3 2025 and a low of -$21.4 million during Q4 2023
  • In the last 5 years, Spyre Therapeutics' Other Non Operating Income had a median value of -$31000.0 in 2021 and averaged $103052.6.
  • Data for Spyre Therapeutics' Other Non Operating Income shows a peak YoY increase of 965833.33% (in 2023) and a maximum YoY decrease of 6675000.0% (in 2023) over the last 5 years.
  • Spyre Therapeutics' Other Non Operating Income (Quarter) stood at -$15000.0 in 2021, then tumbled by 113.33% to -$32000.0 in 2022, then plummeted by 66750.0% to -$21.4 million in 2023, then soared by 96.18% to -$818000.0 in 2024, then skyrocketed by 5029.83% to $40.3 million in 2025.
  • Its Other Non Operating Income stands at $40.3 million for Q3 2025, versus -$656000.0 for Q2 2025 and $2.3 million for Q1 2025.